Biomedical subjects

Mine Harada

Publications and source records attributed to Mine Harada.

189 records · Page 11Linked to original sources

PubMedDate not supplied

Gingival metastasis in lung cancer.

Gingival metastasis is an extremely rare manifestation of lung cancer, and exhibits rapid growth with various clinical symptoms. Physicians must appropriately manage patients with lung cancer who develop gingival metastasis. Clinical records of patients with lung cancer treated at the Department of Internal Medicine II, Okayama University Hospital, between 1976 and 1998 were retrospectively reviewed. The medical literature was searched by Medline to identify reports of gingival metastasis from lung cancer. Three of 729 (0.41%) lung cancer patients developed gingival metastasis in our hospital between 1976 and 1998, and 9 additional cases of this type of metastasis were found in the literature. All were male, and median age was 57.5 years (range, 47 to 70). There were no clear correlations between development of gingival metastasis and either histologic type or location of the primary lesion. Chemotherapy or radiotherapy was effective for treatment of gingival metastasis, and the quality of life was improved. However, survival after development of gingival metastasis was very short, with median survival of only 4 months.

Aged↗

PubMedDate not supplied

Primary signet-ring cell carcinoma of the lung with histochemical characterization.

Signet-ring cell carcinoma (SRCC) is a unique sub-type of mucin-producing adenocarcinoma characterized by abundant intracellular mucin accumulation. Although SRCC has been found in various organs, to the best of our knowledge there have only been a few reports of primary SRCC of the lung. Furthermore, most of the reports describe the coexistence of SRCC with differentiated components, while only one case has been reported as pure SRCC. We report here on a patient with primary SRCC of the lung with histochemical characterization. In our case, the tumor cells were mostly composed of signet-ring cells. Although the patient achieved only a minor response after systemic chemotherapy, he has been doing well, without any further treatment, for 33 months after diagnosis.

Carcinoma, Signet Ring Cell↗

PubMedDate not supplied

Gastric perforation due to metastasis from adenocarcinoma of the lung.

We report a rare case of the development of gastric perforation at the site of metastasis from adenocarcinoma of the lung during systemic chemotherapy. We speculated that the chemotherapy-induced necrosis of the metastatic tumor might have led to the gastric perforation. To the best of our knowledge, this is the first case of chemotherapy-induced gastric perforation as a complication of lung cancer treatment.

Adenocarcinoma↗

PubMedDate not supplied

Tandem high-dose chemotherapy supported by autologous peripheral blood stem cell transplantation for recurrent soft tissue sarcoma.

BACKGROUND: Patients with recurrent soft tissue sarcoma (STS) are seldom curable, with 5-year survival rates of less than 10% in all large series. The role of high-dose chemotherapy (HDC) with hematopoietic stem cell support in this disease has not been established. CASE REPORT: We report on two patients with recurrent STS who were treated with tandem HDC supported by autologous peripheral blood stem cell transplantation (PBSCT). One patient with malignant fibrous histiocytoma recurred with multiple lung metastases. This patient achieved a partial response after two cycles of induction chemotherapy consisting of ifosfamide and epirubicin. During four cycles of induction chemotherapy, peripheral blood stem cells (PBSCs) were harvested. Tandem high-dose ICE regimen (ifosfamide 3 g/m2 on days-7 to -3, carboplatin 400 mg/m2 on days-7, -5 and 3, etoposide 500 mg/m2 on days-7, -5 and 3) supported by autologous PBSCT gave rise to further regression of the tumors. Another patient with malignant hemangiopericytoma was treated by tandem high-dose ICE regimen supported by autologous PBSCT after the 3rd removal of abdominal tumors. Relapse-free intervals until the 1st, 2nd and 3rd relapses were 40, 19 and 22 months, respectively. Tandem high-dose ICE regimen might delay the relapse. CONCLUSION: These observations suggest that a tandem high-dose ICE regimen with autologous PBSCT is feasible with some clinical efficacy in the control of refractory STS.

Adult↗

PubMedDate not supplied

Fractionated administration of irinotecan and cisplatin for treatment of extensive-disease small-cell lung cancer: a phase II study.

BACKGROUND: A combination of irinotecan (CPT-11) and cisplatin (CDDP) was shown to be effective for extensive-disease small-cell lung cancer (ED-SCLC). To take maximum advantage of the synergistic effect between CPT-11 and CDDP, we designed a fractionated administration schedule. PATIENTS AND METHODS: Between August 1995 and September 1998, 15 previously untreated patients with ED-SCLC were enrolled. Both CPT-11 at a dose of 50 mg/m2 and CDDP at a dose of 60 mg/m2 were given on days 1 and 8, and repeated every 4 weeks up to four cycles. RESULTS: Fifteen patients were assessed for response and survival, and fourteen for toxicity. Although twelve patients (80.0%; 95% confidence interval, 51.9-95.7) achieved an objective response, complete response (CR) was not obtained. The median survival time and the actual 1-year survival rate were 9.4 months and 40.0%, respectively. Grade 3 or 4 leukopenia, neutropenia and diarrhea occurred in 71.4%, 100% and 14.3% of the patients, respectively. Enrollment into this study was stopped because CR, which was the primary endpoint, was not obtained in the consecutive 15 patients and the survival appeared to be inferior to the previous multi-institutional study (Kudoh et al, Clin Oncol 16: 1068-1074, 1998). The projected dose intensity in the present study was lower in CPT-11 and higher in CDDP compared to that in the previous report. CONCLUSION: These results suggest that the dose intensity of CPT-11 may have a major role on the activity of SCLC in this combination.

Adult↗

PubMedDate not supplied

Hydronephrosis as a complication of adenocarcinoma of the lung.

We describe a patient with adenocarcinoma of the lung who developed hydronephrosis secondary to compression by right common iliac lymph node metastases. The most common primary sites of cancers causing ureteral obstruction are the cervix, prostate, bladder and colo-rectum. To date, few reports of ureteral obstruction attributable to lung cancer have been published. Although rare, physicians should be aware that hydronephrosis can complicate the course of patients with non-small cell lung cancer.

Adenocarcinoma↗

PubMedDate not supplied

Multicyclic dose-intensive chemotherapy supported by autologous blood progenitor cell transplantation for relapsed small cell lung cancer.

We report two cases with small cell lung cancer (SCLC) receiving multicyclic dose-intensified chemotherapy (DI-CT) supported by autologous blood progenitor cell transplantation (ABPCT). Both cases were initially treated with cisplatin (CDDP), etoposide (ETP) and concurrent thoracic irradiation, however they had recurrent disease within a year. After receiving conventional chemotherapy, they underwent multicyclic DI-CT consisting of CDDP, ETP and ifosfamide supported by G-CSF and ABPCT. Definite regression of the tumors was observed. Severe neutropenia and thrombocytopenia were encountered but they were reversible and no life-threatening complications were experienced. These results suggest the feasibility and effectiveness of multicyclic DI-CT and the usefulness of ABPCT as a treatment option for relapsed SCLC.

Antineoplastic Combined Chemotherapy Protocols↗

PubMedDate not supplied

High frequency of allele-specific down-regulation of HLA class I expression in lung cancer cell lines.

Loss or down-regulation of HLA expression has been demonstrated in various types of solid tumors and is considered to be one of the mechanisms of tumor immunoescape. The effectiveness of immunotherapy using tumor-specific antigens (TSA) largely depends on the expression of the appropriate HLA class I alleles on the tumor cells. We analyzed the allele-specific HLA class I surface expression of six lung cancer cell lines using a broad panel of allele-specific monoclonal antibodies, as well as the effect of IFN-gamma on HLA expression. Flow cytometric analysis displayed a wide range, from minimal to a high degree of expression of monomorphic HLA class I among the studied cell lines. Allele-specific loss or down-regulation of HLA also was observed in 5 out of 6 cell lines. Our results suggest that lung cancer patients considered for specific immunotherapy should be examined with respect to the expression of specific HLA class I allele binding the TSA.

Alleles↗

PubMedDate not supplied

Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines.

Many clinical studies have reported that irinotecan has reproducible antitumor activity against lung cancer. Both cisplatin and SN-38 are key drugs in the treatment of lung cancer, and their combination is one of the most promising regimens available. Using lung cancer cell lines, ABC-1 and SBC-3, we examined the cytotoxic effect of the schedule, as well as the effect of cisplatin on topoisomerase I activity. Cytotoxicity was determined by MTT assay. ABC-1 or SBC-3 cells were incubated with or without various concentrations of both drugs in 96-well microplates for 72 or 96 hours in a humidified 5% CO2 atmosphere at 37 degrees C. Synergism was evaluated by median-effect plot analysis and a combination index isobologram method by Chou and Talalay. After ABC-1 or SBC-3 cells had been exposed to 10/microM cisplatin for one hour, topoisomerase I activities were determined by supercoiled-DNA relaxation assay. Synergism was observed in ABC-1 and SBC-3 cells when cisplatin was given first, followed by SN-38 (7-ethyl-10-hydroxycamptothecin) and cisplatin. Topoisomerase I activity decreased at 1-2 hours after exposure to cisplatin and recovered gradually after 4-5 hours of cisplatin exposure in both ABC-1 and SBC-3 cells. Accordingly, pretreatment with cisplatin will have an impact on the sensitivity to SN-38.

Adenocarcinoma↗